Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114804 | 1.00 | CCR2 (0.48) | CCR2SIGMAR1CCR1CCR5CXCR4 | |
| SCHEMBL1114696 | 0.87 | CCR2 (0.63) | CCR2SIGMAR1CCR1CCR5CXCR4 | |
| SCHEMBL1114824 | 0.79 | SIGMAR1 (0.44) | CCR2SIGMAR1CCR1CCR5CXCR4 | |
| SCHEMBL1114664 | 0.79 | CCR2 (0.43) | CCR2SIGMAR1CCR1CCR5CXCR4 | |
| SCHEMBL1114718 | 0.78 | CA1 (0.41) | CCR2SIGMAR1 | |
| SCHEMBL1114672 | 0.77 | CCR2 (0.60) | CCR2NOD1 | |
| SCHEMBL1114932 | 0.77 | CCR2 (0.60) | CCR2NOD1 | |
| SCHEMBL1114852 | 0.77 | CCR2 (0.60) | CCR2NOD1 | |
| SCHEMBL1114962 | 0.77 | CCR2 (0.60) | CCR2NOD1 | |
| SCHEMBL1114444 | 0.77 | CCR2 (0.60) | CCR2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | disclosed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | SMURF1, SMURF2, PSEN1 | CCR2 1075/4885SIGMAR1 2639/4885CCR1 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.